MRNS
Income statement / Annual
Last year (2023), Marinus Pharmaceuticals, Inc.'s total revenue was $30.99 M,
an increase of 21.63% from the previous year.
In 2023, Marinus Pharmaceuticals, Inc.'s net income was -$141.41 M.
See Marinus Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$30.99 M
|
$25.48 M
|
$15.35 M
|
$1.72 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$1.93 M |
$340,000.00 |
$1.48 M |
$50.51 M |
$503,000.00 |
$127,000.00 |
$126,000.00 |
$23,000.00 |
$11,000.00 |
$0.00 |
| Gross Profit |
$29.06 M |
$25.14 M |
$13.87 M |
-$48.79 M |
-$503,000.00 |
-$127,000.00 |
-$126,000.00 |
-$23,000.00 |
-$11,000.00 |
$0.00 |
| Gross Profit Ratio |
0.94 |
0.99 |
0.9 |
-28.4 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$99.39 M
|
$79.91 M
|
$73.52 M
|
$51.11 M
|
$42.97 M
|
$28.39 M
|
$12.38 M
|
$22.01 M
|
$18.92 M
|
$8.69 M
|
| General & Administrative
Expenses |
$0.00
|
$0.00
|
$37.28 M
|
$18.55 M
|
$11.46 M
|
$8.79 M
|
$6.67 M
|
$6.24 M
|
$5.52 M
|
$3.23 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$61.15 M
|
$56.85 M
|
$37.28 M
|
$18.55 M
|
$11.46 M
|
$8.79 M
|
$6.67 M
|
$6.24 M
|
$5.52 M
|
$3.23 M
|
| Other Expenses |
$0.00 |
$1.17 M |
$657,000.00 |
-$37,000.00 |
-$53,000.00 |
-$1,000.00 |
-$20,000.00 |
-$65,000.00 |
-$7,000.00 |
$1.19 M |
| Operating Expenses |
$160.54 M |
$137.93 M |
$110.80 M |
$69.66 M |
$54.42 M |
$37.18 M |
$19.04 M |
$28.24 M |
$24.43 M |
$11.92 M |
| Cost And Expenses |
$162.47 M |
$138.27 M |
$112.28 M |
$69.66 M |
$54.42 M |
$37.18 M |
$19.04 M |
$28.24 M |
$24.43 M |
$11.92 M |
| Interest Income |
$8.11 M |
$2.35 M |
$80,000.00 |
$499,000.00 |
$354,000.00 |
$454,000.00 |
$324,000.00 |
$128,000.00 |
$64,000.00 |
$12,000.00 |
| Interest Expense |
$16.90 M |
$10.67 M |
$2.58 M |
$0.00 |
$0.00 |
$0.00 |
$159,000.00 |
$464,000.00 |
$475,000.00 |
$117,000.00 |
| Depreciation &
Amortization |
$551,000.00
|
$669,000.00
|
$667,000.00
|
$598,000.00
|
$503,000.00
|
$127,000.00
|
$126,000.00
|
$23,000.00
|
$11,000.00
|
$5,000.00
|
| EBITDA |
-$125.50 M
|
-$5.09 M
|
-$95.53 M
|
-$66.88 M
|
-$54.42 M
|
-$36.60 M
|
-$18.61 M
|
-$28.16 M
|
-$24.36 M
|
-$10.71 M
|
| EBITDA Ratio |
-4.05 |
-0.23 |
-6.27 |
-39.54 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
-4.24
|
-4.43
|
-6.32
|
-39.54
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$11.46 M
|
$96.36 M
|
-$1.85 M
|
$462,000.00
|
$301,000.00
|
$453,000.00
|
$145,000.00
|
-$401,000.00
|
-$418,000.00
|
$1.09 M
|
| Income Before Tax |
-$142.94 M |
-$16.43 M |
-$98.78 M |
-$67.48 M |
-$54.12 M |
-$36.73 M |
-$18.90 M |
-$28.64 M |
-$24.85 M |
-$10.83 M |
| Income Before Tax Ratio
|
-4.61
|
-0.64
|
-6.44
|
-39.28
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$1.54 M |
$3.39 M |
$2.88 M |
-$833,000.00 |
-$354,000.00 |
$453,000.00 |
$13,000.00 |
$399,000.00 |
$468,000.00 |
$1.31 M |
| Net Income |
-$141.41 M |
-$19.82 M |
-$101.66 M |
-$66.64 M |
-$53.77 M |
-$36.73 M |
-$18.90 M |
-$28.64 M |
-$24.85 M |
-$10.83 M |
| Net Income Ratio |
-4.56 |
-0.78 |
-6.62 |
-38.79 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-2.63 |
-0.51 |
-2.77 |
-2.44 |
-3.95 |
-3.59 |
-3.21 |
-5.88 |
-6.66 |
-7.04 |
| EPS Diluted |
-2.63 |
-0.51 |
-2.77 |
-2.44 |
-3.95 |
-3.59 |
-3.21 |
-5.88 |
-6.66 |
-7.04 |
| Weighted Average Shares
Out |
$53.75 M
|
$39.07 M
|
$36.70 M
|
$27.27 M
|
$13.63 M
|
$10.22 M
|
$5.89 M
|
$4.87 M
|
$3.73 M
|
$1.54 M
|
| Weighted Average Shares
Out Diluted |
$53.75 M
|
$39.07 M
|
$36.70 M
|
$27.27 M
|
$13.63 M
|
$10.22 M
|
$5.89 M
|
$4.87 M
|
$3.73 M
|
$1.54 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
